See more : KS Bancorp, Inc. (KSBI) Income Statement Analysis – Financial Results
Complete financial analysis of Akanda Corp. (AKAN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akanda Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Sanyo Special Steel Co., Ltd. (5481.T) Income Statement Analysis – Financial Results
- Mogul Games Group Ltd (MGG.AX) Income Statement Analysis – Financial Results
- Orion Acquisition Corp. (OHPAW) Income Statement Analysis – Financial Results
- Melcor Developments Ltd. (MODVF) Income Statement Analysis – Financial Results
- Hang Seng Bank Limited (HSNGY) Income Statement Analysis – Financial Results
Akanda Corp. (AKAN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.akandacorp.com
About Akanda Corp.
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.16M | 2.62M | 41.43K | 2.06K | 0.00 |
| Cost of Revenue | 2.05M | 649.88K | 756.16K | 1.81K | 198.82K |
| Gross Profit | 111.45K | 1.97M | -714.73K | 253.00 | -198.82K |
| Gross Profit Ratio | 5.16% | 75.19% | -1,725.10% | 12.27% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.88M | 19.85M | 5.81M | 1.36M | 702.41K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.88M | 19.85M | 5.81M | 1.36M | 702.41K |
| Other Expenses | 4.28M | 3.60M | 309.02K | 307.30K | 198.82K |
| Operating Expenses | 10.16M | 23.45M | 6.12M | 1.67M | 901.24K |
| Cost & Expenses | 12.21M | 22.80M | 6.88M | 1.67M | 901.24K |
| Interest Income | 39.00 | 886.00 | 26.75K | 10.19K | 401.00 |
| Interest Expense | 255.66K | 115.32K | 1.09M | 645.16K | 493.81K |
| Depreciation & Amortization | 4.28M | 3.60M | 309.02K | 248.74K | 198.82K |
| EBITDA | -27.74M | -4.52M | -2.15M | -1.41M | -702.01K |
| EBITDA Ratio | -1,284.03% | -626.47% | -15,683.67% | -68,212.22% | 0.00% |
| Operating Income | -10.05M | -20.18M | -6.83M | -1.67M | -901.24K |
| Operating Income Ratio | -465.33% | -770.18% | -16,494.24% | -80,787.34% | 0.00% |
| Total Other Income/Expenses | -22.22M | 11.94M | 96.45K | -634.87K | -493.41K |
| Income Before Tax | -32.28M | -8.24M | -8.13M | -2.30M | -1.39M |
| Income Before Tax Ratio | -1,494.18% | -314.37% | -19,625.88% | -111,569.88% | 0.00% |
| Income Tax Expense | 0.00 | -8.63M | 1.09M | 645.40K | 493.81K |
| Net Income | -32.28M | 397.05K | -9.22M | -2.95M | -1.89M |
| Net Income Ratio | -1,494.18% | 15.16% | -22,263.84% | -142,869.59% | 0.00% |
| EPS | -7.16 | 4.59 | -127.66 | -40.77 | -26.14 |
| EPS Diluted | -7.16 | 4.59 | -127.66 | -40.77 | -26.14 |
| Weighted Avg Shares Out | 4.51M | 86.59K | 72.26K | 72.26K | 72.26K |
| Weighted Avg Shares Out (Dil) | 4.51M | 86.59K | 72.26K | 72.26K | 72.26K |
Akanda Corp. Announces Pricing of Underwritten Public Offering
London, United Kingdom--(Newsfile Corp. - March 25, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announced that it has entered into a firm commitment underwriting agreement with Univest Securities, LLC, as underwriter,...
RETRANSMISSION: Akanda Corp. Signs Share Purchase and Escrow Agreements for the Sale of Portuguese Assets to Somai Pharmaceuticals
London, United Kingdom--(Newsfile Corp. - March 1, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announced the signing of a definitive Share Purchase Agreement and Escrow Agreement with Somai Pharmaceuticals Unipessoal, LDA...
Akanda Corp. Signs Share Purchase and Escrow Agreements for the Sale of Portuguese Assets to Somai Pharmaceuticals
London, United Kingdom--(Newsfile Corp. - February 29, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announced the signing of a definitive Share Purchase Agreement and Escrow Agreement with Somai Pharmaceuticals Unipessoal, LDA...
Akanda Corp. Provides Further Update on Annual Meeting of its Shareholders
London, United Kingdom--(Newsfile Corp. - February 20, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announces that it has received an order from the Ontario Superior Court of Justice (the "Court") permitting...
Akanda Corp. Provides Update on Annual Meeting of its Shareholders
London, United Kingdom--(Newsfile Corp. - February 20, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announces that it has made an application to the Ontario Superior Court of Justice (the "Court") to...
Akanda Corp. Discusses Positive Trends in UK Cannabis Market
London, United Kingdom--(Newsfile Corp. - February 13, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), provides an overview of the growing cannabis market in the United Kingdom and promising trends among patients. 2023 was a dynamic year for...
Akanda Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
London, United Kingdom--(Newsfile Corp. - February 2, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announced that it has closed its previously announced registered direct offering for the sale and issuance of...
Akanda Corp. Provides Update on Scheduling Policy in US Aims to Be Among First International Movers in US Pending Approval
London, United Kingdom--(Newsfile Corp. - February 2, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announces it is actively following the developments in federal US policy to reschedule and/or deschedule cannabis under...
Akanda Corp. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
London, United Kingdom--(Newsfile Corp. - February 2, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announced that it has entered into a securities purchase agreement with certain accredited investors whereby the investors...
Akanda Corp. Entered into Non-Binding Letter of Intent for Sale of RPK
London, United Kingdom--(Newsfile Corp. - February 1, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announces it has entered into an Amended Non-Binding Letter of Intent ("LOI")with Somai Pharmaceuticals Ltd. for the sale...
Source: https://incomestatements.info
Category: Stock Reports